<DOC>
	<DOCNO>NCT01960140</DOCNO>
	<brief_summary>The purpose study determine effect baricitinib time take remove simvastatin body look well-tolerated safe baricitinib give alone combination simvastatin . Side effect document . The study last approximately 7 day first dose end study ( include screen follow-up ) .</brief_summary>
	<brief_title>A Study Baricitinib Simvastatin Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Male participant Agree use 2 reliable method birth control female partner childbearing potential study least 3 month follow last dose study drug Female participant Women childbearing potential due surgical sterilization confirm medical history , menopause Have body mass index 18.0 29.0 kilogram per meter square ( kg/m^2 ) , inclusive Have clinical laboratory test result within normal reference range Have normal renal function Have normal blood pressure pulse rate Are currently enrol clinical trial involve study drug offlabel use drug device , concurrently enrol type medical research Have complete discontinue within last 90 day clinical trial involve study drug Have previously complete withdrawn study study investigate baricitinib , previously receive baricitinib Have know allergy baricitinib , simvastatin , related compound , component baricitinib simvastatin formulation , history significant atopy Have abnormality 12lead electrocardiogram ( ECG ) Have history , current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine ( include hypothyroidism ) , hematological , neurological disorder Have current recent history myalgia muscle weakness Regularly use know drug abuse and/or show positive finding urinary drug screen Have current recent history clinically significant bacterial , fungal , parasitic , viral ( include rhinopharyngitis ) , mycobacterial infection Have symptomatic herpes zoster herpes simplex infection within 90 day prior first dose Have absolute neutrophil count ( ANC ) less 2 × 109/liter ( L ) ( 2000 cells/microliter [ μL ] ) screen day prior first dose study drug . For abnormal value , single repeat allow Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C infection and/or positive hepatitis C antibody Show evidence hepatitis B infection and/or positive hepatitis B surface antigen Are woman lactate Have expose live vaccine within 12 week prior first dose expect need/receive live vaccine ( include herpes zoster vaccination ) course study Intend use overthecounter prescription medication ( include salicylate drug ) and/or herbal supplement within 14 day prior dose study intend use vitamin supplement Day 1 discharge Clinical Research Unit ( CRU ) Have consume intend consume grapefruit grapefruitcontaining product within 14 day prior first dose throughout study Have donate lose blood 500 milliliter ( mL ) within last 3 month Have average weekly alcohol intake exceed 28 unit per week ( male ) 21 unit per week ( female ) , unwilling stop alcohol consumption 48 hour prior first dose discharge Clinical Research Unit ( CRU ) end Period 2 History , opinion investigator , excessive methylxanthine use within previous 6 month , great ( &gt; ) 6 cup coffee ( equivalent ) per day Currently smoke 10 cigarette per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>